

Table of contents

Table of contents

1	General introduction.....	12
1.1	Definition of cardiovascular disease and atherosclerosis	13
1.2	Definition and classification of chronic kidney disease	14
1.3	Prevalence and burden of chronic kidney disease	16
1.4	Increased cardiovascular complications in patients with chronic kidney disease.....	17
1.5	Role of uremic toxins in chronic kidney disease and cardiovascular disease	19
1.6	Diabetes mellitus type II as risk factor of cardiovascular disease and chronic kidney disease.....	20
2	Aims and outline of this thesis.....	22
3	Part I: DPP4 inhibition suppresses thrombus formation in mouse blood without a main role of GLP1 receptor.....	23
3.1	Introduction.....	24
3.1.1	Increased risk of cardiovascular disease in diabetic patients.....	24
3.1.2	Platelets and their role in hemostasis and thrombosis.....	24
3.1.3	Effect of diabetes mellitus on platelet activity	26
3.1.4	Glucagon-like peptide, dipeptidyl peptidase4 and platelets	27
3.1.5	Multi-parameter assessment of thrombus formation under flow	28
3.2	Aims	30
3.3	Methods.....	31
3.3.1	Human blood collection and platelet isolation.....	31
3.3.2	Mouse blood collection.....	31
3.3.3	Complete blood cell count.....	32
3.3.4	DPP activity measurement.....	32
3.3.5	Whole blood thrombus formation	32
3.3.6	Western blot analysis.....	33
3.3.7	RNA isolation and gene expression analysis.....	33

Table of contents

3.3.8	Statistical analysis and heat mapping	35
3.4	Results.....	36
3.4.1	Differential DPP isoform activity in platelet releasate and in platelet-free plasma ...	36
3.4.2	Deficiency or inhibition of DPP4 leads to reduced thrombus formation in mice.....	38
3.4.3	DPP4 inhibition also suppresses thrombus formation in <i>ApoE</i> ^{-/-} mice under hyperlipidemic and hyperglycemic conditions.....	44
3.4.4	No main role for GLP1R on platelets in DPP4- and GLP1-mediated effects on thrombus formation	47
3.4.5	GLP1(7-36) does not alter the phosphorylation state of ERK, AKT and SYK	51
3.5	Discussion	53
4	Part II: Improved removal of hydrophobic uremic toxins from blood via a novel adsorber particle	58
4.1	Introduction.....	59
4.1.1	State of the art: Dialysis techniques	59
4.1.1	Inefficient removal of uremic toxins during conventional dialysis	60
4.1.2	Search for improved dialysis techniques for the removal of uremic toxins	61
4.1.3	Towards improved adsorber particles for improved dialysis efficiency.....	63
4.2	Aims	64
4.3	Methods.....	65
4.3.1	Synthesis of the particles	65
4.3.2	Particle characterization using scanning electron microscopy.....	65
4.3.3	Statement of ethical principle	65
4.3.4	Quantification of adsorption capacity.....	65
4.3.5	Evaluation of hemocompatibility	67
4.3.6	Statistical analysis.....	67
4.4	Results.....	68
4.4.1	Development and characterization of the novel adsorber particle	68
4.4.2	Evaluation of the adsorber capacity	71
4.4.3	Assessment of hemocompatibility according to ISO-norm 10993-4.....	73

Table of contents

4.5	Discussion	76
5	General discussion.....	80
5.1	Reduction of thrombus formation by DPP4 inhibition and GLP1 mimetics: alternative to traditional antiplatelet therapy?	81
5.2	Towards improved dialysis techniques: adsorption of hydrophobic uremic toxins	83
6	References.....	85
7	List of Figures	94
8	List of Tables.....	96
9	Supplement.....	97
9.1	Tables part I.....	97
9.2	Materials	100
9.2.1	General laboratory equipment.....	100
9.2.2	General consumables	101
9.2.3	Chemicals and reagents	101
9.2.4	Buffers and solutions.....	103
9.2.5	Antibodies	104
9.2.6	Kits.....	105
9.2.7	Mice	105
9.2.8	Software.....	105
9.3	Publications	106
9.4	Oral and poster presentations	107
9.5	Curriculum Vitae	108